Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Transplant Proc ; 49(10): 2333-2339, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29198673

ABSTRACT

BACKGROUND: Total pancreatectomy (TP) is offered as a last treatment option for pain relief in patients with chronic pancreatitis. Concurrent islets autotransplantation (TP-IAT) may improve glucose control. METHODS: We analyzed results in 20 recent patients who underwent TP-IAT at The University of Chicago. The median observation period was 28 months (2-38). Data were collected prospectively then analyzed retrospectively. RESULTS: The number of patients requiring opioids daily for pain control decreased from 16 (80%) prior to surgery to 2 (13%) 1 year after, with only 1 (6.5%) patient experiencing persistent phantom pancreatic pain. Opioid requirements decreased from a median 56.3 (0-240) morphine equivalent dose to 5 (0-130) on day 75 and to 0 (0-30) at 1-year follow up. Five patients (25%) completely stopped insulin support prior to day 75 while maintaining hemoglobin A1c of 5.9% (5-6.3). Eight (53%) patients were insulin free at 1 year with A1c of 6% (5.5-6.8) and a similar rate persisted in next 2 years. For the remaining patients, the more islet function that was preserved, the less insulin they required and A1c was closer to optimal. Quality of Life (QoL) measured by SF36 Physical (PCS) and Mental (MCS) Component Score improved on day 75 (P < .001) and maintained improvement later on. Both PCS and MCS improved regardless of whether patient requires insulin support or not. CONCLUSIONS: Improvements of QoL with pain resolution and good glucose control can be achieved after TP-IAT in properly selected patients with CP and intractable pain, regardless of patient insulin support status.


Subject(s)
Blood Glucose , Islets of Langerhans Transplantation/methods , Pain, Postoperative/epidemiology , Pancreatectomy/adverse effects , Pancreatitis, Chronic/surgery , Quality of Life , Adult , Female , Humans , Islets of Langerhans Transplantation/adverse effects , Male , Middle Aged , Pain Management , Pancreatectomy/methods , Retrospective Studies , Transplantation, Autologous , Treatment Outcome
2.
Aliment Pharmacol Ther ; 33(1): 149-59, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21083584

ABSTRACT

BACKGROUND: Effectiveness of medical therapies in chronic pancreatitis has been described in small studies of selected patients. AIM: To describe frequency and perceived effectiveness of non-analgesic medical therapies in chronic pancreatitis patients evaluated at US referral centres. METHODS: Using data on 516 chronic pancreatitis patients enrolled prospectively in the NAPS2 Study, we evaluated how often medical therapies [pancreatic enzyme replacement therapy (PERT), vitamins/antioxidants (AO), octreotide, coeliac plexus block (CPB)] were utilized and considered useful by physicians. RESULTS: Oral PERT was commonly used (70%), more frequently in the presence of exocrine insufficiency (EI) (88% vs. 61%, P < 0.001) and pain (74% vs. 59%, P < 0.002). On multivariable analyses, predictors of PERT usage were EI (OR 5.14, 95% CI 2.87-9.18), constant (OR 3.42, 95% CI 1.93-6.04) or intermittent pain (OR 1.98, 95% CI 1.14-3.45). Efficacy of PERT was predicted only by EI (OR 2.16, 95% CI 1.36-3.42). AO were tried less often (14%) and were more effective in idiopathic and obstructive vs. alcoholic chronic pancreatitis (25% vs. 4%, P = 0.03). Other therapies were infrequently used (CPB - 5%, octreotide - 7%) with efficacy generally <50%. CONCLUSIONS: Pancreatic enzyme replacement therapy is commonly utilized, but is considered useful in only subsets of chronic pancreatitis patients. Other medical therapies are used infrequently and have limited efficacy.


Subject(s)
Abdominal Pain/therapy , Antioxidants/therapeutic use , Gastrointestinal Agents/therapeutic use , Octreotide/therapeutic use , Vitamins/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Autonomic Nerve Block/methods , Enzyme Replacement Therapy , Female , Humans , Male , Middle Aged , Pancreas/pathology , Pancreatitis, Chronic , Prospective Studies , Surveys and Questionnaires , Treatment Outcome , United States , Young Adult
4.
Am J Physiol ; 276(2): C306-11, 1999 02.
Article in English | MEDLINE | ID: mdl-9950757

ABSTRACT

We have shown that endocytosis at the apical plasma membrane of pancreatic acinar cells is regulated by the pH of the acinar lumen and is associated with cleavage of GP2, a glycosyl phosphatidylinositol-anchored protein. The aim of this study was to determine the transduction pathway by which endocytosis is activated. Apical endocytosis was studied in rat pancreatic acini by prestimulation with cholecystokinin followed by measurement of horseradish peroxidase (HRP) uptake. Lanthanum, staurosporine, and forskolin had no effect on HRP uptake. Cytochalasin D significantly inhibited endocytosis, indicating a dependence on actin filament integrity. Genistein and the specific tyrphostin inhibitor B42 also inhibited HRP uptake, implicating tyrosine kinases in the regulation of HRP uptake. With the use of an Src kinase-specific substrate, Src kinase activity was temporally related to activation of endocytosis. The tyrosine-dependent phosphorylation of an 85-kDa substrate in both rat and mouse pancreatic acini correlated with Src kinase activation and pH-dependent regulation of HRP uptake. These results indicate that apical endocytosis in acinar cells is associated with tyrosine kinase activation and is dependent on the actin cytoskeleton.


Subject(s)
Endocytosis/physiology , Pancreas/physiology , Protein-Tyrosine Kinases/physiology , Animals , Cell Membrane/physiology , Enzyme Activation/physiology , Horseradish Peroxidase/pharmacokinetics , Hydrogen-Ion Concentration , Male , Mice , Mice, Inbred C57BL , Pancreas/cytology , Pancreas/enzymology , Phosphoproteins/metabolism , Rats , Rats, Wistar , Signal Transduction/physiology , Tyrosine/metabolism , src-Family Kinases/metabolism
5.
Trans R Soc Trop Med Hyg ; 91(2): 150-2, 1997.
Article in English | MEDLINE | ID: mdl-9196753

ABSTRACT

A new region with human onchocerciasis is reported in the Unturán mountains, South Venezuela, affecting Yanomamö populations not surveyed in previous studies conducted in the Venezuelan-Brazilian border area. Its distribution probably extends towards the Upper Toototobi endemic area in Brazil. The age-standardized prevalence of Onchocerca volvulus microfilariae (mf) (67%), the prevalence of infection in those aged > or = 20 years (86%), and the community microfilarial load (CMFL) (24 mf/mg), are consistent with hyperendemic transmission. Both prevalence and mean intensity increased monotonically with age without reaching a plateau, the highest values being recorded in the > or = 45 years age class (respectively, 95% and 42 [geometric mean of Williams] or 172 [arithmetic mean] mf/mg). The degree of parasite overdispersion (measured by the variance/mean ratio) also increased with host age. The CMFL value, the presence of sclerosing keratitis, hanging groin, and severe skin lesions, indicated that the infection poses an important public health problem in the region.


Subject(s)
Endemic Diseases , Indians, South American , Onchocerciasis/epidemiology , Skin Diseases, Parasitic/epidemiology , Adolescent , Adult , Age Distribution , Animals , Child , Female , Humans , Keratitis/complications , Male , Microfilariae , Middle Aged , Onchocerciasis/complications , Onchocerciasis/parasitology , Prevalence , Sex Distribution , Skin Diseases, Parasitic/complications , Skin Diseases, Parasitic/parasitology , Venezuela/epidemiology
6.
Proc Assoc Am Physicians ; 108(6): 455-66, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8956369

ABSTRACT

Infected patients are likely to have increased levels of tumor necrosis factor-alpha (TNF-alpha) and may be treated with recombinant human granulocyte colony-stimulating factor (G-CSF). Recombinant human TNF-alpha activates polymorphonuclear neutrophil (PMN) inflammatory activity. We examined the effect of exposure to TNF-alpha and G-CSF alone and in combination on PMN apoptosis, receptor expression, phagocytosis, and bactericidal function. The results were compared to those obtained with a promoter of PMN apoptosis, cycloheximide. After 24 hr, 27% of PMNs were nonapoptotic, and TNF-alpha (1 unit/ml) showed no change. Cycloheximide (10 micrograms/ml) decreased the number of nonapoptotic cells to 10% of the initial PMN. In contrast, G-CSF (30 ng/ml) decreased apoptosis (57% nonapoptotic PMN after 24 hr). Both G-CSF and TNF-alpha (but not cycloheximide) induced preservation of PMN Fc gamma RIII (467% and 167% of 24-hr controls, respectively) and beta 2-integrin expression (150% and 168% of 24-hr controls, respectively). G-CSF (but not TNF-alpha or cycloheximide) stimulated expression of Fc gamma RI (191% of 24-hr control) and Fc gamma RII (267% of 24-hr control). G-CSF (but not TNF-alpha) maintained the ability of PMN to ingest and kill opsonized Staphylococcus aureus. TNF-alpha decreased the effect of G-CSF on apoptosis, expression of Fc gamma RIII and Fc gamma RI, and bactericidal function. Thus, TNF-alpha promoted expression of Fc gamma RIII and beta 2-integrin receptors, which are important for phagocytic activity, and G-CSF diminished apoptosis, increased Fc gamma receptor expression, and maintained bactericidal function. TNF-alpha counteracted some effects of G-CSF. Interactions of these cytokines in vivo serve to regulate the PMN inflammatory response and bactericidal capacity.


Subject(s)
Apoptosis/physiology , Granulocyte Colony-Stimulating Factor/physiology , Neutrophil Activation/physiology , Neutrophils , Tumor Necrosis Factor-alpha/physiology , Cells, Cultured , Humans , Neutrophils/microbiology , Neutrophils/pathology , Neutrophils/physiology , Phagocytosis/physiology , Staphylococcus aureus
SELECTION OF CITATIONS
SEARCH DETAIL
...